<bill session="115" type="h" number="1776" updated="2019-04-18T16:05:45Z">
  <state datetime="2017-03-29">REFERRED</state>
  <status>
    <introduced datetime="2017-03-29"/>
  </status>
  <introduced datetime="2017-03-29"/>
  <titles>
    <title type="official" as="introduced">To improve access to affordable prescription drugs.</title>
    <title type="short" as="introduced">Improving Access To Affordable Prescription Drugs Act</title>
    <title type="short" as="introduced">Improving Access To Affordable Prescription Drugs Act</title>
    <title type="display">Improving Access To Affordable Prescription Drugs Act</title>
  </titles>
  <sponsor bioguide_id="S001145"/>
  <cosponsors>
    <cosponsor bioguide_id="B001300" joined="2017-04-25"/>
    <cosponsor bioguide_id="C001080" joined="2017-06-06"/>
    <cosponsor bioguide_id="C001068" joined="2017-06-23"/>
    <cosponsor bioguide_id="C000714" joined="2017-04-06"/>
    <cosponsor bioguide_id="C000984" joined="2017-03-29"/>
    <cosponsor bioguide_id="D000191" joined="2017-10-24"/>
    <cosponsor bioguide_id="D000216" joined="2017-03-29"/>
    <cosponsor bioguide_id="E000288" joined="2017-04-25"/>
    <cosponsor bioguide_id="G000551" joined="2017-04-05"/>
    <cosponsor bioguide_id="J000298" joined="2017-09-06"/>
    <cosponsor bioguide_id="K000389" joined="2018-07-25"/>
    <cosponsor bioguide_id="M001185" joined="2018-11-27"/>
    <cosponsor bioguide_id="M001143" joined="2017-07-26"/>
    <cosponsor bioguide_id="N000127" joined="2017-05-18"/>
    <cosponsor bioguide_id="N000147" joined="2018-05-21"/>
    <cosponsor bioguide_id="P000258" joined="2017-04-06"/>
    <cosponsor bioguide_id="P000597" joined="2017-05-18"/>
    <cosponsor bioguide_id="P000607" joined="2017-04-05"/>
    <cosponsor bioguide_id="R000515" joined="2017-05-16"/>
    <cosponsor bioguide_id="R000577" joined="2017-10-24"/>
    <cosponsor bioguide_id="S001170" joined="2017-04-25"/>
    <cosponsor bioguide_id="V000108" joined="2017-11-01"/>
    <cosponsor bioguide_id="W000800" joined="2017-03-29"/>
  </cosponsors>
  <actions>
    <action datetime="2017-03-29">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-03-29" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-03-29">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-03-29">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-03-31">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2017-04-05">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSWM" name="House Ways and Means" activity="Referral"/>
    <committee subcommittee="Health" code="HSWM02" name="House Ways and Means" activity="Referral"/>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="" code="HSJU" name="House Judiciary" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="115" relation="unknown" number="6340"/>
    <bill type="s" session="115" relation="unknown" number="252"/>
    <bill type="s" session="115" relation="unknown" number="348"/>
    <bill type="s" session="115" relation="unknown" number="469"/>
    <bill type="s" session="115" relation="unknown" number="3411"/>
    <bill type="s" session="115" relation="unknown" number="2478"/>
    <bill type="s" session="115" relation="identical" number="771"/>
    <bill type="h" session="115" relation="unknown" number="1245"/>
    <bill type="s" session="115" relation="unknown" number="2476"/>
    <bill type="s" session="115" relation="unknown" number="1688"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Administrative remedies"/>
    <term name="Business records"/>
    <term name="Canada"/>
    <term name="Cancer"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Congressional oversight"/>
    <term name="Consumer affairs"/>
    <term name="Corporate finance and management"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Executive agency funding and structure"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Government trust funds"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health programs administration and funding"/>
    <term name="Income tax deductions"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Judicial review and appeals"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Research and development"/>
    <term name="Retail and wholesale trades"/>
    <term name="Trade restrictions"/>
    <term name="User charges and fees"/>
    <term name="Veterans' medical care"/>
  </subjects>
  <amendments/>
  <summary date="2017-03-29T04:00:00Z" status="Introduced in House">This bill amends provisions of various laws relating to prescription-drug pricing and affordability.&#160;Specifically, the bill:

 expands reporting requirements for drug manufacturers&#160;and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures; requires the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program; requires the GAO to report to Congress on such negotiations conducted by the CMS; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance,&#160;for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program; modifies provisions related to the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; establishes a prize fund for new and more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; modifies provisions related to drug exclusivity; allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.</summary>
  <committee-reports/>
</bill>
